SAB Biotherapeutics, Inc.

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

SAB Biotherapeutics announced it will issue third quarter 2026 financial results on the morning of Thursday, November 5, 2026, with a conference call and webcast at 08:30 AM ET. The release contains no financial figures; it is purely a scheduling notice with dial-in details. SAB BIO is a clinical-stage biotech whose lead candidate SAB-142 is in Phase 2b (SAFEGUARD) and Phase 3 (PRISE-hATG) trials for type 1 diabetes; business updates may accompany the results.

•3d ago

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

SAB Biotherapeutics announced that management will participate in the Chardan 10th Annual Healthcare Conference with a fireside chat on October 20, 2026, at 11:15 a.m. ET in New York. CEO Samuel J. Reich will present, and management will be available for one-on-one meetings; webcast registration and replays are available via the company's website. The release contains no new data, but it reiterates that lead candidate SAB-142 is in a registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 autoimmune type 1 diabetes patients.

•18d ago

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

SAB Biotherapeutics will present encore Phase 1 data for SAB-142, its lead fully human anti-thymocyte immunoglobulin candidate for Stage 3 type 1 diabetes, at the inaugural Breakthrough T1D Clinical & Research Congress on October 9-11, 2026 in Philadelphia. Presentations include two oral sessions covering sustained autoimmune balance with induction/maintenance dosing and C-peptide signals in adults more than 100 days post diagnosis, plus three ePosters on PK, redosing safety, and binding specificity. SAB-142 remains in the registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients; no new efficacy or safety results were disclosed in this announcement.

•1mo ago

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

SAB Biotherapeutics (Nasdaq: SABS) will present data on its lead program SAB-142 at the 62nd Annual Meeting of the European Association for the Study of Diabetes, held September 28 through October 2, 2026 in Milan, Italy. Four oral presentations will cover SAB-142 Phase 1 findings, including mechanism of action, safe redosing with no immunogenicity, predictable PK/PD profiles, and early C-peptide preservation and efficacy signals in adults with recent-onset type 1 diabetes. SAB-142 is a fully human anti-thymocyte globulin currently being evaluated in the registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients; the EASD data are early Phase 1 signals rather than new registrational results.

•1mo ago

SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics announced that management will participate in the Citi Biopharma Back to School Conference on September 10 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14. CEO Samuel J. Reich is scheduled to present a fireside chat at the Citi event, while the company will conduct one-on-one meetings at the Morgan Stanley conference. SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing immunoglobulins, with its lead candidate SAB-142 currently in a registrational Phase 2b trial for Type 1 Diabetes.

•2mo ago

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SAB Biotherapeutics announced it will release its second quarter 2026 financial results on the morning of Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a business update. The company remains focused on its lead candidate SAB-142, which is currently in a registrational Phase 2b clinical trial for autoimmune type 1 diabetes.

•3mo ago

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB Biotherapeutics announced it will release its first quarter 2026 financial results on the morning of May 12, 2026, followed by a conference call and webcast at 8:30 AM ET to discuss the results and business updates. The company's lead candidate, SAB-142, is currently being evaluated in a registrational Phase 2b clinical trial called SAFEGUARD for newly diagnosed Stage 3 autoimmune Type 1 Diabetes patients. Investors can access the live call via registration on the company's website, with a replay made available shortly after under the Investors & Media section.

•5mo ago